NewAmsterdam Pharma vs Stoke Therapeutics
NAMS and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAMS and STOK compare
NewAmsterdam Pharma grew revenue faster over the last twelve months (−26.4% versus −86.2% for Stoke Therapeutics).
Stoke Therapeutics keeps more of each dollar of sales as profit, with a net margin of −754% compared with −790% at NewAmsterdam Pharma.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | STOK |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.7B |
| Share price | $20.14 | $26.68 |
| Change, 1 year | −47.4% | 6.2% |
| Change, 5 years | 105% | −4.0% |
| Beta (5Y) | 0.83 | 1.62 |
| Employees | 100 | 170 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 62.4× |
| P/B | – | 5.0× |
| FCF yield | – | −10.5% |
| Fair value | – | $9.57 |
| Margin of safety | – | −179% |
| Growth | ||
| Revenue growth (TTM) | −26.4% (better) | −86.2% |
| Net income growth (TTM) | – | −496% |
| EPS growth (TTM) | – | −501% |
| Profitability | ||
| Operating margin | −900% | −810% (better) |
| Net margin | −790% | −754% (better) |
| FCF margin | −582% (better) | −655% |
| Return on equity | −30.2% (better) | −61.1% |
| Return on invested capital | −1333% | −252% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −4856.0× |
| Current ratio | 11.76 (better) | 7.69 |
| Altman Z-score | – | 18.22 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 120% |
| Held by insiders | 22.0% | 41.6% |
| Insider net buying, 12 months | −$63.0M | −$6.7M (better) |
| Short interest, % of float | – | 28.5% |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- STOK stock overview
- STOK income statement
- STOK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.